{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.7","upperLimit":"8.4","value":"6.7"},{"groupId":"OG001","lowerLimit":"3.9","upperLimit":"15","value":"6.8"},{"groupId":"OG002","lowerLimit":"2.8","upperLimit":"11.8","value":"5.26"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"40"}],"units":"Participants"}],"description":"PFS was calculated for all randomized patients from the day of randomization until the first observation of disease progression (date of objective relapse or progression of Relapse/Progression Report) or death due to any cause (recorded in Date/Cause of Death Section of Death Report).","dispersionType":"95% Confidence Interval","groups":[{"description":"Pemetrexed 500 mg/m2 IV Day 1 every 21 days for 6 cycles Cisplatin 75 mg/m2 IV Day 1 every 21 days for 6 cycles\n\nCisplatin\n\nPemetrexed","id":"OG000","title":"Arm A - Cisplatin/Pemetrexed"},{"description":"Pembrolizumab 200 mg\\* IV Day 1 over 30 min every 21 days for a total of 2 years Pemetrexed 500 mg/m2 IV Day 1 every 21 days for 6 cycles Cisplatin 75 mg/m2 IV Day 1 every 21 days for 6 cycles\n\nCisplatin\n\nPemetrexed\n\nPembrolizumab","id":"OG001","title":"Arm B - Cisplatin/Pemetrexed/Pembrolizumab"},{"description":"Pembrolizumab 200 mg\\* IV 30 min Day 1 every 21 days for a total of 2 years\n\nPembrolizumab","id":"OG002","title":"Arm C - Pembrolizumab (Phase II Only)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"PFS was monitored continuously, with assessments every 6 weeks for 3 visits, then every 12 weeks, 4 weeks post-discontinuation, every 12 weeks until progression, and every 24 weeks until death, over an average of 16.2 months.","title":"Phase II: Progression Free Survival Measured as Time From Randomization to First Observation of Objective Disease Relapse or Progression","type":"PRIMARY","unitOfMeasure":"months"}